A Phase 2 interventional study of CTP-543 and CTP-543 matching placebo in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 13 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-19.
Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 2, and was the 1st registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:
Sun Pharma Japan Limited · Sites in Japan
Ages 18–65
Sun Pharmaceutical Industries, Inc. · Sites in United States, Canada
Ages 12–17
By country, each count listing its studies:
Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6
First in 2017; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 336 across the 10 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Concert Pharmaceuticals, one of the names counted as Sun Pharmaceutical Industries Limited. Under that name alone:
Concert Pharmaceuticals is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited: 2 open now, 3 under way, 3 of them phase 3. Of 7 finished, 7 (100%) have results posted.
Among the 10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 2, and was the 1st registered.
Sun Pharmaceutical Industries Limited’s Alopecia Areata studies by the year they started, since 2017.
1 of the studies testing deuruxolitinib in Alopecia Areata that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sun Pharmaceutical Industries Limited’s 10 in Alopecia Areata:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.
This is a double-blind, randomized, placebo-controlled multi-center study consisting of 3 cohorts to assess the safety and efficacy of CTP-543. Each Cohort will be initiated sequentially in ascending dose order. Participants will be randomized to either an active dose of CTP-543 or placebo for a 24-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive CTP-543 4 mg tablets, twice daily for up to 24 weeks.
Drug: CTP-543
Participants will receive CTP-543 8 mg tablets, twice daily for up to 24 weeks.
Drug: CTP-543
Participants will receive CTP-543 12 mg tablets, twice daily for up to 24 weeks.
Drug: CTP-543
Participants will receive CTP-543 matched placebo tablets, twice daily for up to 24 weeks in Cohorts 1, 2, and 3.
Drug: CTP-543 matching placebo
Administered as tablets.
Administered as tablets.
Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Responders were defined as participants achieving at least a 50% relative reduction in SALT score from baseline at Week 24.
Time frame: Week 24
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event. TEAE is defined as any adverse event that occurs after administration of the first dose of study drug.
Time frame: From first dose of study drug up to safety follow up at Week 28
Participants were enrolled at 13 study centers in the United States from 09 August 2017 to 08 July 2019.
| Milestone | Combined Placebo | Cohort 1: CTP-543 4 mg BID | Cohort 2: CTP-543 8 mg BID | Cohort 3: CTP-543 12 mg BID |
|---|---|---|---|---|
| Started | 44 | 30 | 38 | 37 |
| Safety population | 44 | 29 | 38 | 36 |
| Completed | 35 | 23 | 30 | 36 |
| Not completed | 9 | 7 | 8 | 1 |
| Withdrew: Adverse event | 3 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 1 | 0 | 1 |
| Withdrew: Withdrawal by investigator | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 4 | 3 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 |
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Responders were defined as participants achieving at least a 50% relative reduction in SALT score from baseline at Week 24.
| Percentage of participants | Combined Placebo | Cohort 1: CTP-543 4 mg BID | Cohort 2: CTP-543 8 mg BID | Cohort 3: CTP-543 12 mg BID |
|---|---|---|---|---|
| Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24 | 9.3 | 21.4 | 47.4 | 58.3 |
An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event. TEAE is defined as any adverse event that occurs after administration of the first dose of study drug.
| Participants | Combined Placebo | Cohort 1: CTP-543 4 mg BID | Cohort 2: CTP-543 8 mg BID | Cohort 3: CTP-543 12 mg BID |
|---|---|---|---|---|
| Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) | 31 | 25 | 31 | 30 |
Collected over From first dose of study drug up to safety follow up at Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combined Placebo | 0/44 (0%) | 0/44 (0%) | 31/44 (70.5%) |
| Cohort 1: CTP-543 4 mg BID | 0/29 (0%) | 0/29 (0%) | 25/29 (86.2%) |
| Cohort 2: CTP-543 8 mg BID | 0/38 (0%) | 0/38 (0%) | 31/38 (81.6%) |
| Cohort 3: CTP-543 12 mg BID | 0/36 (0%) | 1/36 (2.8%) | 30/36 (83.3%) |
| Event | Combined Placebo | Cohort 1: CTP-543 4 mg BID | Cohort 2: CTP-543 8 mg BID | Cohort 3: CTP-543 12 mg BID |
|---|---|---|---|---|
| CellulitisInfections and infestations | 0/44 | 0/29 | 0/38 | 1/36 |
| Event | Combined Placebo | Cohort 1: CTP-543 4 mg BID | Cohort 2: CTP-543 8 mg BID | Cohort 3: CTP-543 12 mg BID |
|---|---|---|---|---|
| HeadacheNervous system disorders | 4/44 | 5/29 | 10/38 | 7/36 |
| NasopharyngitisInfections and infestations | 1/44 | 3/29 | 3/38 | 9/36 |
| Upper respiratory tract infectionInfections and infestations | 7/44 | 2/29 | 2/38 | 7/36 |
| AcneSkin and subcutaneous tissue disorders | 2/44 | 4/29 | 4/38 | 6/36 |
| NauseaGastrointestinal disorders | 4/44 | 4/29 | 4/38 | 1/36 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/44 | 4/29 | 1/38 | 2/36 |
| Low density lipoprotein increasedInvestigations | 0/44 | 0/29 | 4/38 | 0/36 |
| FolliculitisInfections and infestations | 0/44 | 3/29 | 2/38 | 1/36 |
| Blood creatine phosphokinase increasedInvestigations | 1/44 | 3/29 | 2/38 | 1/36 |
| DiarrheaGastrointestinal disorders | 3/44 | 3/29 | 1/38 | 0/36 |
Randomized population included all the randomized participants.
| Age, Continuous(years) | Combined Placebo | Cohort 1: CTP-543 4 mg BID | Cohort 2: CTP-543 8 mg BID | Cohort 3: CTP-543 12 mg BID | Total |
|---|---|---|---|---|---|
| Mean | 37.8 ± 13.50 | 35.7 ± 11.01 | 37.3 ± 14.18 | 35.8 ± 12.37 | 36.8 ± 12.85 |
| Sex: Female, Male(Participants) | Combined Placebo | Cohort 1: CTP-543 4 mg BID | Cohort 2: CTP-543 8 mg BID | Cohort 3: CTP-543 12 mg BID | Total |
|---|---|---|---|---|---|
| Female | 29 | 22 | 26 | 28 | 105 |
| Male | 15 | 8 | 12 | 9 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Combined Placebo | Cohort 1: CTP-543 4 mg BID | Cohort 2: CTP-543 8 mg BID | Cohort 3: CTP-543 12 mg BID | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 4 | 3 | 15 |
| Not Hispanic or Latino | 39 | 26 | 33 | 34 | 132 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Combined Placebo | Cohort 1: CTP-543 4 mg BID | Cohort 2: CTP-543 8 mg BID | Cohort 3: CTP-543 12 mg BID | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 2 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 7 | 2 | 7 | 3 | 19 |
| White | 33 | 25 | 26 | 30 | 114 |
| Other | 1 | 1 | 3 | 0 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Jul 2019, 22 months.
Results were first posted in Jul 2022, 3 years after primary completion. A results delay was requested in Jul 2020.
Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 22 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deuruxolitinib